Being "at risk" for Alzheimer's means having a higher probability of developing it, not receiving a diagnosis or learning your fate. Before symptoms, the phrase can describe either risk factors or Alzheimer's-related biomarker changes—and those are not the same thing. Risk factors estimate likelihood from age, genes, family history, health, and lifestyle. Biomarkers may detect disease-related biology while memory and thinking remain normal, but they cannot tell exactly whether or when symptoms will appear.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What raises the probability?
- Genetic risk is not always inherited Alzheimer's
- Can Alzheimer's biology exist without symptoms?
- Should someone without symptoms get biomarker testing?
- What can you do with elevated risk?
What raises the probability?
Age is the biggest known risk factor. The National Institute on Aging estimates that about one in 13 people aged 65–84 and one in three aged 85 or older live with Alzheimer's. Fewer than 10% of cases occur before age 65, according to the National Institute on Aging's overview of causes and risk factors.
Family history also matters. Having a parent or sibling with Alzheimer's raises risk, but it does not establish that another family member will develop the disease. Health and lifestyle can shift probability as well. No single factor—whether age, family history, or a health condition—provides a personal forecast.
Genetic risk is not always inherited Alzheimer's
APOE ε4 is a risk variant. It increases the chance of Alzheimer's and is associated with earlier onset in some populations, but some carriers never develop the disease. Rare variants in APP, PSEN1, and PSEN2 are different.
They carry a very strong probability of Alzheimer's before age 65. Each child of a carrier has a 50% chance of inheriting that variant, according to the National Institute on Aging. This distinction changes how a genetic result should be understood: Before pursuing genetic testing, ask what gene is being tested and whether the result estimates risk or indicates a rare inherited variant.
- An APOE result modifies risk; it does not predict an individual outcome.
- An APP, PSEN1, or PSEN2 variant may indicate a rare inherited form with much stronger implications.
- A family history alone does not reveal which genetic situation, if either, applies.
Can Alzheimer's biology exist without symptoms?
yes. Amyloid and tau are proteins associated with Alzheimer's, and certain tests can detect abnormal patterns before measurable cognitive problems appear. Under the 2024 Alzheimer's Association criteria, a cognitively unimpaired person with qualifying abnormal "Core 1" biomarkers is considered to have Alzheimer's pathology biologically.
That is more specific than simply having risk factors. However, the person remains at risk of developing symptoms; the result does not establish when symptoms will begin or guarantee that they will. The Alzheimer's Association Workgroup criteria are a framework for defining and staging the disease. They are not a step-by-step clinical-practice guideline.
Should someone without symptoms get biomarker testing?
Routine biomarker diagnosis is not recommended for cognitively unimpaired people outside observational or treatment research. Disease-targeted therapies have not been approved for people without symptoms. The FDA-cleared Lumipulse blood test does not change that position. It is not a screening test for healthy adults.
The test is intended for adults aged 55 or older who show signs and symptoms of cognitive decline and are being evaluated in specialized care. False results can occur, so clinicians must interpret the test alongside a clinical evaluation. The FDA's May 2025 clearance notice specifically limits its intended use rather than supporting population-wide screening. For someone with normal cognition, a commercial test result may create a label without providing a clear treatment decision. Before testing, clarify:.
- Whether the test is intended for people without symptoms.
- Whether it measures general risk or qualifying Alzheimer's biomarkers.
- What action would follow a positive, negative, or uncertain result.
- Whether the result requires confirmation and clinical interpretation.
What can you do with elevated risk?
Focus first on health factors that can be changed. These include blood pressure, diabetes, smoking, alcohol misuse, inactivity, hearing loss, sleep, diet, and social isolation.
Addressing them supports a practical risk-reduction plan, but it should not be presented as a guarantee. Researchers cannot yet say that changing these factors prevents dementia. Start with concrete, manageable actions:.
- Review blood pressure, diabetes, hearing, sleep, smoking, and alcohol use with a healthcare professional.
- Choose regular physical activity that fits your health and mobility.
- Maintain social contact instead of treating brain health as only a medical issue.
- Discuss persistent changes in memory or thinking rather than relying on a consumer screening result.
- Ask what a proposed genetic or biomarker test would change before agreeing to it.
